A. Bossios (Stockholm, Sweden), E. Kelly (Dublin 4, Ireland)
Including the ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials), these formats showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, session chairs and viewers will take part lively discussions on the presented trials.
Dose response of icenticaftor in patients with COPD and chronic bronchitis on triple inhaled therapy
F. Franssen (Maastricht, Netherlands), F. Martinez (New York, United States), J. Wedzicha (London, United Kingdom), J. Eckert (Basel, Switzerland), B. Knorr (New Jersey, United States), R. Parlikar (Hyderabad, India), A. Tanase (Basel, Switzerland), C. Gessner (Leipzig, Germany)
|    |
Point of care blood eosinophil guided oral prednisolone for COPD exacerbations: a multi-centre double blind randomised controlled trial (The STARR2 trial)
S. Ramakrishnan (Oxford, United Kingdom), H. Jeffers (Oxford, United Kingdom), B. Langford-Wiley (Oxford, United Kingdom), J. Davies (Oxford, United Kingdom), M. Mahdi (Oxford, United Kingdom), C. A'Court (Carterton, United Kingdom), I. Binnian (Eyensham, United Kingdom), S. Bright (Witney, United Kingdom), S. Cartwright (Faringdon, United Kingdom), R. Fox (Bicester, United Kingdom), R. Russell (Oxford, United Kingdom), M. Bafadhel (London, United Kingdom)
| |
Bronchodilators in Symptomatic Tobacco-exposed Persons with Preserved Spirometry for the RETHINC Study Group
M. Han (Ann Arbor, United States), W. Ye (Ann Arbor, United States), D. Wang (Ann Arbor, United States), E. White (Ann Arbor, United States), M. Arjomandi (San Francisco, United States), I. Barjaktarevic (Los Angeles, United States), S. Brown (Baltimore, United States), R. Buhr (Los Angeles, United States), A. Comellas (Iowa City, United States), C. Cooper (Los Angeles, United States), G. Criner (Philadelphia, United States), M. Dransfield (Philadelphia, United States), F. Drescher (White River Junction, United States), R. Folz (Houston, United States), N. Hansel (Baltimore, United States), R. Kaner (New York, United States), R. Kanner (Salt Lake City, United States), J. Krishnan (Chicago, United States), S. Lazarus (San Francisco, United States), V. Maddipati (Greenville, United States), F. Martinez (New York, United States), A. Matthews (Durham, United States), C. Meldrum (Ann Arbor, United States), C. Mcevoy (Bloomington, United States), T. Nyunoya (Pittsburgh, United States), L. Rogers (New York, United States), W. Stringer (Los Angeles, United States), C. Wendt (Minneapolis, United States), R. Wise (Baltimore, United States), S. Wisniewski (Pittsburgh, United States), F. Sciurba (Pittsburgh, United States), P. Woodruff (San Francisco, United States)
| |
Wrap-up by discussant and discussion
D. Singh (Manchester, United Kingdom)
| |
Randomized, rater-blinded, controlled study of intravenous (IV) N-acetylcysteine (NAC) in hospitalized adults with respiratory tract disease and abnormal mucus secretion
W. Tang (Shanghai, China), D. Zhu (Jinhua, China), X. Zhang (Shanghai, China), V. Zanin (Bresso (Mi), Italy), P. Magrone (Bresso (Mi), Italy), A. Papi (Ferrara, Italy), J. Qu (Shanghai, China)
| |
High-flow nasal cannula versus noninvasive ventilation in the prevention of escalation to invasive mechanical ventilation in patients with acute hypoxemic respiratory failure
G. Agmy (Assiut, Egypt), M. Adam (Assiut, Egypt), M. Elkhawaga (Assiut, Egypt), E. Hsanen (Assiut, Egypt)
| |
Awake Prone Positioning in Acute Hypoxemic Respiratory Failure from COVID-19: A Randomized Clinical Trial
W. Alhazzani (Hamilton, Canada), K. Parhar (Calgary, Canada), J. Weatherald (Calgary, Canada), Z. Al Duhailib (Riyadh, Saudi Arabia), M. Alshahrani (Dammam, Saudi Arabia), A. Al-Fares (Kuwait City, Kuwait), S. Buabbas (Kuwait City, Kuwait), S. Cherian (Houston, United States), L. Munshi (Toronto, Canada), E. Fan (Toronto, Canada), F. Al-Hameed (Jeddah, Saudi Arabia), J. Chalabi (Al Ahsa, Saudi Arabia), A. Rahmatullah (Riyadh, Saudi Arabia), E. Duan (Hamilton, Canada), J. Tsang (Hamilton, Canada), K. Lewis (Hamilton, Canada), F. Lauzier (Québec City, Canada), J. Centofanti (Hamilton, Canada), B. Rochwerg (Hamilton, Canada), S. Culgin (Hamilton, Canada), K. Nelson (Hamilton, Canada), S. Abdukahil (Riyadh, Saudi Arabia), K. Fiest (Calgary, Canada), H. Stelfox (Calgary, Canada), H. Tlayjeh (Riyadh, Saudi Arabia), M. Meade (Hamilton, Canada), D. Perri (Hamilton, Canada), K. Solverson (Calgary, Canada), D. Niven (Calgary, Canada), R. Lim (Calgary, Canada), M. Møller (Copenhagen, Denmark), E. Belley-Cote (Hamilton, Canada), L. Thabane (Hamilton, Canada), H. Tamim (Beirut, Lebanon), D. Cook (Hamilton, Canada), Y. Arabi (Riyadh, Saudi Arabia)
| |
Wrap-up by discussant and discussion
F. Franssen (Horn, Netherlands)
| |